MRI detects prostate cancer better than conventional TRUS biopsy, and is implemented through e-communication

Posted on April 3, 2012 by

This is a lecture by Dr. Jelle Barentz.

Professor of Radiology

Prostate MR-Center of Excellence

Department of Radiology

Radboud University Nijmegen Medical Centre

The Netherlands

Topic:  MRI detects prostate cancer better than conventional TRUS biopsy, and is implemented through e-communication.

This video was produced by : TEDx Maastricht

Posted in Biopsy, Diagnosis, Imaging, MRI, Prostate Cancer, Treatments for Prostate Cancer | Tagged , | 1 Comment

New Treatments For Castration Resistant Prostate Cancer

Posted on April 1, 2012 by

For the Ask Dr Barken Call In Show on

Tuesday, April 3rd at 6pm Pacific

Time:  Dial 1-877-727-3301 to hear the program.

Question of the week:

  

For castration resistant prostate cancer,

is it better to do Provenge first or Zytiga first?

Video Blog Presentation:

Dr. Barken interviews Dr. Mark Scholz from Prostate

Cancer Oncology.  An important question discussed is 

how to sequence new treatments approved by the FDA.

The related article of the week:

Immunotherapy for Prostate Cancer: Recent Advances,

Lessons Learned, and Areas for Further Research.

Clin Cancer Res; 17(12); 3884–91.  J. L. Gulley and C.G. Drake

Posted in Castration Resistant Prostate Cancer, Immune Therapy, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer | Tagged , , , | Leave a comment

P 53- a prognostic test for prostate cancer.

Posted on March 26, 2012 by

Question of the week:

 What is P53 and how is it used as a prognostic test?

The related article of the week:

P53 protein expression status and recurrence in

men treated with radiation and androgen suppression

therapy for higher-risk prostate cancer: a prospective

phase II Cancer and Leukemia Group B Study

(CALGB 9682) D’Amico AV : Urology 2008 May;71(5):933-7

Video Blog Presentation:

Dr. Barken answers the questions and presents a video

commentary about P53, a tumor marker on the Coaching Checklist.

Posted in Checklist, Coaching, Markers, Prognosis, Prostate Cancer, Treatments for Prostate Cancer | Tagged | Leave a comment

What is Prolactin and why is it important?

Posted on March 20, 2012 by

Question of the week:  

What is Prolactin and why is it important?   

The article of the week:

Prolactin in men’s health and disease.  Alexander

Bolyakov; Current Opinion in Urology 2011, 21:527–534

 

Dr. Barken answers the questions and presents a video commentary about Prolactin. 

For the Ask Dr Barken Call In Show on

Tuesday, March 20th at 6pm Pacific

Time:  Dial 1-877-727-3301 to hear the program.

You can upload past shows from the web site www.pcref.org

Posted in Castration Resistant Prostate Cancer, Checklist, Coaching, Hormonal Blockade, Journal Club, Markers, Metastatic Disease, Sexual Dysfunction, Survival prostate cancer, Testosterone, Treatments for Prostate Cancer | Tagged , | Leave a comment

Radium-223 ( Alpharadin): A novel Radiopharmaceutical that Prolongs Survival in Bone Metastatic Disease

Posted on March 13, 2012 by
 

The following question is for the Ask Dr Barken

Call In Show on Tuesday, March 13th at 6pm Pacific

Time.  Dial 1-877-727-3301 to hear the program.

Where can I get Alpharadin? What criteria will I need to meet to get this treatment?


 

The related article of the week:

Radium-223: A novel radio-pharmaceutical that prolongs

survival in advanced prostate cancer.   Oliver Sartor M.D.

Prostate Cancer Communication Volume 28, No 1, pp 9, March 2012 ( PAACT Newsletter – Richard Profit, Editor and President)

Video Blog Presentation:
Dr. Barken answers the questions and presents a video
commentary about the expanded access to the following
study:  Radium-223 Chloride (Alpharadin) in Castration-
Resistant Prostate Cancer Patients.
Posted in Ask Dr. Barken, Bone Metastases, Castration Resistant Prostate Cancer, Metastatic Disease, Metastatic Prostate Cancer Disease, Prostate Cancer, Radiation treatment, Survival prostate cancer, Treatments for Prostate Cancer | Tagged , | Leave a comment

Stromal Targeted Therapy in Bone Metastatic Disease

Posted on March 6, 2012 by
The following question is for the Ask Dr Barken
Call In Show on Tuesday, March 6th at 6pm Pacific
Time.  Dial 1-877-727-3301 to hear the program.

Question of the week:  

 When should I start treating my bone metastatic disease?
 

The Article of the Week:

Stromal targeted therapy in bone metastatic

prostate cancer: promise delivered

Oliver Sartor, William Goeckeler and Oyvind Bruland3

Asian Journal of Andrology (2011) 13, 783–784;

Published online: 22 August 2011

Posted in Bone Metastases, Castration Resistant Prostate Cancer, Hormone Refractory Disease, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer | Tagged , , , | Leave a comment

Castration Resistant Prostate Cancer- Immunotherapy or Chemotherapy?

Posted on February 28, 2012 by

Chemotherapy or Immunotherapy for Advanced Castration Resistant Prostate Cancer

Question of the week:  
 
Should I start chemotherapy or immunotherapy for
advanced castration resistant prostate cancer?
 
 
Dr. Barken will answer the question and present a
related response by Dr. James Gulley, NCI, Head of
Immunological Studies.
Dr. Barken answers the questions and presents a video
commentary about selecting treatments for Castration
Resistant Prostate Cancer.
Posted in Ask Dr. Barken, Castration Resistant Prostate Cancer, Coaching, Immune Therapy, Metastatic Disease, Metastatic Prostate Cancer Disease, Prostate Cancer, Treatments for Prostate Cancer | Leave a comment